New drug combo aims to control Hard-to-Treat cancers
NCT ID NCT03162627
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including breast, digestive, female/male genital, and thyroid cancers). The first phase finds the safest dose, and the second phase checks if that dose can help control the cancer. Up to 90 participants will take part at MD Anderson Cancer Center.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF BREAST are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.